Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Venmax Drugs & Pharmaceuticals Ltd (VENMAX) is currently trading at 16.68 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Venmax Drugs & Pharmaceuticals Limited (VDPL) is primarily engaged in pharmaceutical product manufacturing, focusing on drug intermediaries and APIs. Recently, the company has ventured into establishing a chain of medical stores under the 'Ananya Pharma' brand, supported by its formulations plant, Suzichem Labs. Originally established in 1998, VDPL has undergone several name changes, reflecting its evolving business strategy and market positioning. As part of its diversification, VDPL is also involved in IT and ITES services, indicating a strategic move to broaden its revenue streams.
Over the past 52 weeks, Venmax Drugs & Pharmaceuticals Ltd has traded between a low of ₹15.56 and a high of ₹36.96. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Venmax Drugs & Pharmaceuticals Ltd has a market capitalization of approximately 19.32. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Venmax Drugs & Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 96.60 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 19.32 Cr, Venmax Drugs & Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Venmax Drugs & Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Venmax Drugs & Pharmaceuticals Ltd is 96.60. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
4
Neutral
7
Bullish
3
Bearish
36
Neutral
7
Bullish
3
Bearish
32
Neutral
0
Bullish
0
Preferential Allotment/QIP
Venmax Drugs & Pharmaceuticals allotted 7,53,334 equity shares to Dinesh Muddu Kotian on conversion of warrants at Rs.20 each; Board approved on July 30, 2026; paid-up capital increased to Rs.14,48,39,290.
Preferential Allotment/QIP
Venmax Drugs approved conversion of 7,53,334 warrants into equity on July 30, 2026 at Rs.20 per share to Dinesh Muddu Kotian, raising paid-up capital to Rs.14,48,39,290 and total shares to 1,44,83,929.
Preferential Allotment/QIP
Venmax Drugs: Board approved conversion of 21,47,665 warrants into equity on July 29, 2026 at Rs.20/share; company received Rs.3,22,14,975; paid-up capital increases to Rs.13,73,05,950 (1,37,30,595 shares).
Preferential Allotment/QIP
Venmax Drugs & Pharmaceuticals Ltd: 8 warrant holders converted 21,47,665 preferential warrants into equity at Rs.20/share; company received Rs.3,22,14,975; paid-up capital increased to Rs.13,73,05,950. Board met on 2026-07-29.
Venmax Drugs & Pharmaceuticals Limited (VDPL) is primarily engaged in pharmaceutical product manufacturing, focusing on drug intermediaries and APIs.
Recently, the company has ventured into establishing a chain of medical stores under the 'Ananya Pharma' brand, supported by its formulations plant, Suzichem Labs.
Originally established in 1998, VDPL has undergone several name changes, reflecting its evolving business strategy and market positioning.
As part of its diversification, VDPL is also involved in IT and ITES services, indicating a strategic move to broaden its revenue streams.
Pharmaceuticals & Biotechnology
Pharmaceuticals
19 Cr
Low Risk
96.6
37.5
-0.1
1.4
36.96
15.56
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
75.27 | 23 Cr | 28.86 | 1.95 | 0.00 | 6.73 | 9.78 | 6.19 | ||
16.68 | 19 Cr | 96.60 | 1.37 | 0.00 | 1.76 | 1.92 | 1.23 | ||
34.55 | 19 Cr | 12.60 | 0.81 | 0.00 | 6.49 | 7.62 | 0.44 | ||
31.00 | 18 Cr | 30.98 | 1.36 | 0.00 | 4.23 | 5.80 | 2.73 | ||
9.95 | 18 Cr | 50.23 | 0.56 | 0.00 | 1.12 | 4.42 | 0.29 | ||
3.20 | 17 Cr | -155.36 | 2.30 | 0.00 | 0.07 | 0.33 | 0.00 | ||
25.00 | 15 Cr | -60.28 | 0.00 | 0.00 | 20.74 | -104.17 | -21.01 | ||
| Median: 7 Co. | — | 25.00 | 18 Cr | 28.86 | 1.36 | 0.00 | 4.23 | 4.42 | 0.44 |
